SOUTH SAN FRANCISCO, Calif.,
May 29, 2014 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that
James M. Gower, the company's
chairman and chief executive officer, is scheduled to present a
company overview at the Jefferies 2014 Global Healthcare Conference
in New York City on Tuesday, June 3rd at 2:30
p.m. ET.
To access the live audio webcast or the subsequent archived
recording, log on to www.rigel.com. Please connect to Rigel's
website several minutes prior to the start of the live webcast to
ensure adequate time for any software download that may be
necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc. is a clinical-stage drug development company that
discovers and develops novel, small-molecule drugs for the
treatment of inflammatory and autoimmune diseases, as well as
muscle disorders. Rigel's pioneering research focuses on
intracellular signaling pathways and related targets that are
critical to disease mechanisms. Rigel currently has five product
candidates in development: fostamatinib, an oral SYK inhibitor
expected to enter Phase 3 clinical trials for ITP in the second
quarter of 2014 and a Phase 2 clinical trial for IgA nephropathy in
the second half of 2014; R348, a topical JAK/SYK inhibitor
currently in Phase 2 clinical trials for dry eye; R118, an AMPK
activator in Phase 1 development; and two oncology product
candidates in Phase 1 development with partners BerGenBio
and Daiichi Sankyo.
Follow us on Twitter - @RigelPharma
Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com
SOURCE Rigel Pharmaceuticals, Inc.